LFHM: Targeting Genomic Biomarkers for Diagnosis and Therapy

Wednesday, May 22 2013 11:30am - 1:30pm Eastern Time Presented by:

Recent approaches to drug discoveries focus upon the better understanding of the biochemical pathways that govern the pathogenesis of diseases at a molecular level.  Previous studies have shown that malignant cells of many cancers expressed on their surface in high density, a genomic product VPAC1 combined for vasoactive intestinal and pituitary adenylate cyclase activating peptide.  These finger prints, the receptors, encode G protein, involved in cell proliferation, differentiation and cell survival.  On benign or normal cells, only a few VPAC1 receptors are present.  We therefore hypothesized that targeting VPAC1 using a specific biomolecule labeled with a positron emitting radionuclide will permit us not only to image early cancers of the breast (BC), prostate (PC) and lung (LC), but will also distinguish benign lesions from malignant masses.  Early data shall be presented.


Presenter: Mathew L. Thakur, Ph.D

Title: Director, Laboratories of Pharmaceutical Research & Molecular Imaging
        Professor of Radiology and Radiation Oncology

Affiliation: Thomas Jefferson University

April 05, 2013
April 05, 2013
University City Science Center

Core Operating Processes:


Wednesday, May 22 2013 11:30am - 1:30pm Eastern Time
Location: Quorum
3711 Market Street, University City Science Center
Philadelphia, PA 19104